利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

172 条记录 (耗时 0.038 秒)

    Process for preparing a pharmaceutical formulation of contrast agents
    33.
    发明授权
    Process for preparing a pharmaceutical formulation of contrast agents 有权
    一种用于制备造影剂的药物制剂的方法

    公开(公告)号：EP2799090B9

    公开(公告)日：2016-12-21

    申请号：EP14165008.5

    申请日：2009-02-18

    申请人： GUERBET

    发明人： Meyer, Dominique ,  Corot, Claire ,  Port, Marc ,  Barbotin, Vincent ,  Bonnemain, Bruno

    IPC分类号： A61K49/10 ,  A61K51/04

    摘要： The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, D03A, BT-D03A, HP-D03A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C ch1 and/or of free lanthanide C lan 1 ; d) adjustment of C ch 1 and/or of C lan 1 so as to obtain C ch 1 = Ct ch 1 and C lan 1 = 0, wherein C t ch 1 is the target concentration of free macrocyclic chelate in the final liquid pharmaceutical formulation.

    MAGNETO-EMULSION VECTORISEE
    34.
    发明公开
    MAGNETO-EMULSION VECTORISEE 有权
    矢量磁乳液

    公开(公告)号：EP2948185A1

    公开(公告)日：2015-12-02

    申请号：EP14701522.6

    申请日：2014-01-23

    申请人： Guerbet

    发明人： ROBIC, Caroline ,  PORT, Marc

    IPC分类号： A61K49/18 ,  B82Y15/00

    CPC分类号： A61K49/1806 ,  A61K49/1839 ,  A61K49/1887 ,  B82Y15/00

    摘要： The invention relates to an oil-in-water nanoemulsion composition for MRI, comprising an aqueous phase, a lipid phase in the form of nanodroplets comprising an oil and magnetic particles (p) based on an iron compound and covered by at least one C8-C22 fatty acid, and a mixture of surfactants at the interface between the aqueous and lipid phases, the surfactant mixture comprising at least one amphiphilic lipid and at least one amphiphilic targeting ligand. The invention also relates to the production method of said composition and to the uses of same.

    Process for preparing a pharmaceutical formulation of contrast agents
    35.
    发明公开
    Process for preparing a pharmaceutical formulation of contrast agents 有权
    制备造影剂药物制剂的方法

    公开(公告)号：EP2799090A3

    公开(公告)日：2015-01-14

    申请号：EP14165008.5

    申请日：2009-02-18

    申请人： GUERBET

    发明人： Meyer, Dominique ,  Corot, Claire ,  Port, Marc ,  Barbotin, Vincent ,  Bonnemain, Bruno

    IPC分类号： A61K49/10 ,  A61K51/04

    摘要： The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, said process comprising the following successive steps:
    b) preparation of a liquid pharmaceutical composition containing the complex of macrocyclic chelate with a lanthanide, free macrocyclic chelate that is not under the form of an excipient X[X',L] in which L is the macrocyclic chelate and X and X' are a metal ion, in particular chosen independently from calcium, sodium, zinc and magnesium, and/or free lanthanide,
    said step b) consisting in the preparation of a solid complex [chelate-lanthanide] and in the dissolution of the said complex in water ;
    c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C ch 1 or of free lanthanide C lan 1 ;
    d) adjustment of C ch 1 and/or of C lan 1 by adding to the formulation obtained in step b) :
    - if C lan 1 > 0 and/or C ch 1 ch 1 , free macrocyclic chelate,
    - if C lan 1 = 0 and C ch 1 > C t ch 1 , free lanthanide,

    so as to obtain C ch 1 = C t ch 1 and C lan 1 = 0 wherein Ct ch 1 is the target concentration of the free macrocyclic chelate in the final liquid pharmaceutical formulation and is selected in the range of between 0.002 % and 0.4 % mol/mol,
    wherein the amount of free macrocyclic chelate in the final liquid pharmaceutical formulation corresponds to the proportion of free macrocyclic chelate relative to the amount of complexed macrocyclic chelate in the final liquid pharmaceutical formulation.

    摘要翻译： 本发明涉及制备含有大环螯合物与镧系元素的复合物和摩尔/摩尔量的游离大环螯合物的液体药物制剂的方法，所述方法包括以下连续步骤：b）制备 的包含大环螯合物与镧系元素的游离大环螯合物的液体药物组合物，其不是以赋形剂X [X'，L]的形式存在，其中L是大环螯合物，X和X'是金属离子 ，尤其是选自钙，钠，锌和镁，和/或游离镧​​系元素，所述步骤b）包括制备固体配合物[螯合物 - 镧系元素]并将所述配合物溶于水中; c）在步骤b）获得的药物制剂中测量游离大环螯合物Cch 1或游离镧系元素族1的浓度; d）通过向步骤b）中获得的制剂中加入Cch 1和/或Clan 1进行调节： - 如果Clan 1> 0和/或Cch 1 Ct ch 1，游离镧系元素，以便获得Cch 1 = Ct ch 1和Clan 1 = 0，其中Ct ch 1是最终液体药物制剂中游离大环螯合物的目标浓度，并且选择范围 为0.002％至0.4％摩尔/摩尔，其中最终液体药物制剂中游离大环螯合物的量对应于游离大环螯合物相对于最终液体药物制剂中络合大环螯合物的量的比例。

    PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF CONTRAST AGENTS
    36.
    发明授权
    PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF CONTRAST AGENTS 有权
    方法制备药物染料制剂

    公开(公告)号：EP2242515B9

    公开(公告)日：2014-10-01

    申请号：EP09712403.6

    申请日：2009-02-18

    申请人： GUERBET

    发明人： MEYER, Dominique ,  COROT, Claire ,  PORT, Marc ,  BARBOTIN, Vincent ,  BONNEMAIN, Bruno

    IPC分类号： A61K49/10

    CPC分类号： A61K49/108 ,  A61K9/0019 ,  A61K31/28 ,  A61K45/06 ,  A61K47/18 ,  A61K49/106 ,  G01N33/15

    摘要： The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, D03A, BT-D03A, HP-D03A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C ch1 and/or of free lanthanide C lan 1 ; d) adjustment of C ch 1 and/or of C lan 1 so as to obtain C ch 1 = Ct ch 1 and C lan 1 = 0, wherein C t ch 1 is the target concentration of free macrocyclic chelate in the final liquid pharmaceutical formulation.

    NANOEMULSION DE CHELATE POUR IRM
    37.
    发明公开
    NANOEMULSION DE CHELATE POUR IRM 有权

    公开(公告)号：EP2654802A1

    公开(公告)日：2013-10-30

    申请号：EP11802928.9

    申请日：2011-12-20

    申请人： Guerbet ,  Université de Bordeaux 1

    发明人： PORT, Marc ,  ROBIC, Caroline ,  LEAL CALDERON, Fernando ,  CHADEL, Samy

    IPC分类号： A61K49/18

    CPC分类号： A61K49/1809 ,  A61K49/1806

    摘要： The present invention relates to an oil-in-water nanoemulsion composition for MRI, including: an aqueous phase which is 70 to 90 wt % of the composition, advantageously 75 to 85 wt %, more advantageously 78 to 82 wt %; a lipid phase including an oil, which is 9.5 to 29.5 wt % of the composition, advantageously 14 to 25 wt %, more advantageously 17 to 21 wt %; a surfactant at the interface between the aqueous and lipid phases, the surfactant including at least one amphiphilic paramagnetic metal chelate and optionally an amphiphilic lipid; the total content by weight of the surfactant relative to the oil being 4 to 10 wt %, advantageously 5 to 8 wt %; the total content by weight of the surfactant relative to the composition being 0.35 to 2.95 wt %, advantageously 0.5 to 2 wt %; the oil including at least 70 wt %, advantageously at least 80 wt %, more advantageously at least 95 wt %, in particular at least 97 wt %, of C6-C18 saturated fatty acids, advantageously C6-C14, and more advantageously C6-C10.

    摘要翻译： 本发明涉及一种用于MRI的水包油纳米乳液组合物，其包含：水相，其占组合物的70-90wt％，有利地75-85wt％，更有利地78-82wt％; 包含油的脂质相，其为组合物的9.5至29.5重量％，有利地为14至25重量％，更有利地为17至21重量％; 在水相和脂质相之间的界面处的表面活性剂，所述表面活性剂包含至少一种两亲性顺磁性金属螯合物和任选的两亲性脂质; 表面活性剂相对于油的总重量含量为4至10重量％，有利地为5至8重量％; 表面活性剂相对于组合物的总重量含量为0.35-2.95重量％，有利地为0.5-2重量％; 所述油包含至少70重量％，有利地至少80重量％，更有利地至少95重量％，特别地至少97重量％的C 6 -C 18饱和脂肪酸，有利地为C 6 -C 14，并且更有利地为C 6 -C 14饱和脂肪酸， C10。

    Composes pour le diagnostique de l'apoptose
    39.
    发明公开
    Composes pour le diagnostique de l'apoptose 有权
    Verbindungen zur Diagnose der Apoptose

    公开(公告)号：EP2474553A2

    公开(公告)日：2012-07-11

    申请号：EP12163474.5

    申请日：2008-03-21

    申请人： GUERBET

    发明人： Port, Marc ,  Rousseaux, Olivier ,  Muller, Robert ,  Burtea, Carmen

    IPC分类号： C07K7/06 ,  A61K49/08 ,  A61K49/14 ,  A61K49/18 ,  C07D257/02 ,  C07D403/06 ,  B82Y5/00 ,  G01N33/68

    CPC分类号： A61K49/186 ,  A61K49/085 ,  A61K49/14 ,  A61K49/1863 ,  A61K49/1866 ,  B82Y5/00 ,  C07D257/02 ,  C07D403/06 ,  C07K7/06

    摘要： La présente invention concerne un Composé de formule générale (I) suivante :
    Signal - Lien - Peptide (I) dans laquelle Signal représente une entité signal ; Lien, présent ou non, représente une liaison chimique et Peptide représente un peptide comprenant un peptide ciblant l'apoptose, le peptide ciblant l'apoptose étant choisi parmi les peptides de formule suivante et leurs équivalents fonctionnels:
    - X1-X2-X3-X4-X5-X6 (1) (SEQ ID No 1) dans laquelle X1 et X2 représentent indépendamment l'un de l'autre la leucine ou l'isoleucine, X3 et X4 représentent la lysine, X5 représente la proline et X6 représente la phénylalanine, avantageusement le peptide L-I-K-K-P-F (SEQ ID No 11) et ses équivalents fonctionnels.
    - D-A-H-S-X7-S (2) (SEQ ID No 2) dans laquelle X7 représente la phénylalanine ou la leucine ;
    - P-G-D-L-X8-X9 (3) (SEQ ID No 3) dans laquelle X8 représente la sérine ou la valine et X9 représente la thréonine ou l'arginine ;
    - H-G-X10-L-S-X11 (4) (SEQ ID No 4) dans laquelle X10 représente l'acide aspartique ou l'histidine, et X11 représente la thréonine ou l'isoleucine ;
    - V-L-G-E-R-G (5) (SEQ ID No 5);

    et les sels pharmaceutiquement acceptables de ces composés.

    摘要翻译： 信号是信号实体，可以存在的肽化合物（信号肽 - 肽）是化学键，肽是包含肽靶向凋亡的肽的肽及其功能等同物及其盐，是新的 。 信号为信号实体，键（任选存在）的式（信号键 - 肽）（I）的肽化合物是化学键，肽是包含靶向凋亡的肽的肽，其包含式X1-X2的肽 -X3-X4-X5-X6（SEQ ID NO：1），优选Leu-Ile-Lys-Lys-Pro-Phe（SEQ ID NO：11）及其功能等同物，式Asp-Ala-His- Ser-X7-Ser（SEQ ID NO：2），式Pro-Gly-Asp-Leu-X8-X9（SEQ ID NO：3）的肽，式His-Gly-X10-Leu-Ser- X11（SEQ ID NO：4）和式Val-Leu-Gly-Glu-Arg-Gly（SEQ ID NO：5）的肽及其功能等同物和盐是新的。 X1，X2：亮氨酸或异亮氨酸; X3，X4：赖氨酸; X5：脯氨酸 X6：苯丙氨酸; X7：苯丙氨酸或亮氨酸; X8：丝氨酸或缬氨酸; X9：苏氨酸或精氨酸; X10：天冬氨酸或组氨酸; 和X11：苏氨酸或异亮氨酸。 独立权利要求包括：（1）用于医学成像的组合物，其包含（I）和赋形剂，用于肠胃外给药; 和（2）组合物的制备，包括在包含赋形剂的可注射培养基中加入（I）。